| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 124 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64 |
| Body Types | Overweight |
Supplementation of _l. reuteri_ NCIMB 30242 at 2.9x10^9^ CFU twice daily in otherwise healthy hypercholesteromic adults for nine weeks did not appear to confer any significant toxic effects relative to placebo.Funding issues for this study:
LDL cholesterol appeared to be reduced 11.7% with supplementation, but most other parameters were unchanged.
Funding provided by Micropharma, producer of Cardioviva
